REFERENCES
- Seguin R, Biernacki K, Prat A, et al. Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. Glia 2003; 42: 36–45
- O'Keefe GM, Nguyen VT, Benveniste EN. Regulation and function of class It major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neuro-logical diseases. I Neurovirol 2002; 8: 496–512
- Neumann H. Control of glial immune function by neurons. Glia 2001; 36: 191–199
- Santambrogio L, Belyanskaya SL, Fischer FR, et al. Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA 2001; 98: 6295–6300
- Flugel A, Labeur MS, Grasbon-Frodl EM, et al. Microglia only weakly present glioma antigen to cytotoxic T cells. Int I Dev Neurosci 1999; 17: 547–556
- Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol (Berl) 2002; 103: 351–355
- Hickey WE, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988; 239: 290–292
- Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. ] Virol 1998; 72: 9873–9880
- Schamboeck A, Korman AJ, Kamb A, et al. Organization of the transcriptional unit of a human class II histocompatibility antigen: HLA-DR heavy chain. Nucleic Acids Res 1983; 11: 8663–8675
- Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871–875
- Naldini, L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263–267
- Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 2000; 7: 910–913
- Cui Y, Golob J, Kelleher E, et al. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 2002; 99: 399–408
- Mittelbronn M, Dietz K, Schluesener FIJ, et al. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol (Berl) 2001; 101: 249–255
- Butter C, Healey DG, Agha N, et al. An immunoelectron microscopical study of the expression of class II MHC and a T lymphocyte surface marker during chronic relapsing experi-mental allergic encephalomyelitis. J Neuroimmunol 1988; 20: 45–51
- Wang CC, Wu CH, Shieh JY, et al. Microglial distribution and apoptosis in fetal rat brain. Brain Res Dev Brain Res 2002; 139: 337–342
- Cuadros MA, Moujahid A, Quesada A, et al. Development of microglia in the quail optic tectum. I Comp Neurol 1994; 348: 207–224
- Schwab JM, Schluesener HJ, Seid K, et al. IL-16 is diffe-rentially expressed in the developing human fetal brain by microglial cells in zones of neuropoesis. Int I Dev Neurosci 2001; 19: 93–100
- Dorries R. The role of T-cell-mediated mechanisms in virus infections of the nervous system. Curr Top Microbiol Immunol 2001; 253: 219–245
- Santambrogio L, Pakaski M, Wong ML, et al. Antigen presenting capacity of brain microvasculature in altered peptide ligand modulation of experimental allergic encephalomyelitis. J Neuroimmunol 1999; 93: 81–91
- van der Maesen K, Hinojoza JR, Sobel RA. Endothelial cell class II major histocompatibility complex molecule expression in stereo-tactic brain biopsies of patients with acute inflammatory/demye-linating conditions. ] Neuropathol Exp Neurol 1999; 58: 346–358
- DiMeco F, Rhines LD, Hanes J, et al. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. I Neurosurg 2000; 92: 419–427
- Ewend MG, Thompson RC, Anderson R, et al. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J Immunother 2000; 23: 438–448
- Hanes J, Sills A, Zhao Z, et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 2001; 18: 899–906
- Lesniak MS, Tyler BM, Pardoll DM, et al. Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2. J Neurooncol 2003; 64: 155–160
- Sampath P, Hanes H, DiMeco F, et al. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 1999; 59: 2107–2114
- Thompson RC, Pardoll DM, Jaffee EM, et al. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. I Immunother Emphasis Tumor Immunol 1996; 19: 405–413